TY - JOUR
T1 - Prognostic value of 18F-FDG PET/CT in patients with soft tissue sarcoma
T2 - Comparisons between metabolic parameters
AU - Hong, Sun Pyo
AU - Lee, Seung Eun
AU - Choi, Yoon La
AU - Seo, Sung Wook
AU - Sung, Ki Sun
AU - Koo, Hong Hoe
AU - Choi, Joon Young
PY - 2014/5
Y1 - 2014/5
N2 - Objectives: To investigate the relationship between volume-based PET parameters and prognosis in patients with soft tissue sarcoma (STS). Methods: We retrospectively reviewed 55 patients with pathologically proven STS who underwent pretreatment with 18 F-Fluorodeoxyglucose ( 18F-FDG) PET/CT. The maximum standardized uptake value (SUV max), average SUV (SUVavg), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of primary tumors were measured using a threshold SUV as liver activity for determining the boundary of tumors. Univariate and multivariate survival analyses for overall survival were performed according to the metabolic parameters and other clinical variables. Results: Cancer-related death occurred in 19 of 55 patients (35 %) during the follow-up period (29 ± 23 months). On univariate analysis, AJCC stage (stage IV vs. I-III, hazard ratio (HR) = 2.837, p = 0.028), necrosis (G2 vs. G0-G1, HR = 3.890, p = 0.004), SUVmax (1 unit - increase, HR = 1.146, p = 0.008), SUVavg (1 unit - increase, HR = 1.469, p = 0.032) and treatment modality (non-surgical therapy vs. surgery, HR = 4.467, p = 0.002) were significant predictors for overall survival. On multivariate analyses, SUVmax (HR = 1.274, p = 0.015), treatment modality (HR = 3.353, p = 0.019) and necrosis (HR = 5.985, p = 0.006) were identified as significant independent prognostic factors associated with decreased overall survival. Conclusions: The SUVmax of the primary tumor is a significant independent metabolic prognostic factor for overall survival in patients with STS. Volume-based PET parameters may not add prognostic information outside of the SUVmax.
AB - Objectives: To investigate the relationship between volume-based PET parameters and prognosis in patients with soft tissue sarcoma (STS). Methods: We retrospectively reviewed 55 patients with pathologically proven STS who underwent pretreatment with 18 F-Fluorodeoxyglucose ( 18F-FDG) PET/CT. The maximum standardized uptake value (SUV max), average SUV (SUVavg), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of primary tumors were measured using a threshold SUV as liver activity for determining the boundary of tumors. Univariate and multivariate survival analyses for overall survival were performed according to the metabolic parameters and other clinical variables. Results: Cancer-related death occurred in 19 of 55 patients (35 %) during the follow-up period (29 ± 23 months). On univariate analysis, AJCC stage (stage IV vs. I-III, hazard ratio (HR) = 2.837, p = 0.028), necrosis (G2 vs. G0-G1, HR = 3.890, p = 0.004), SUVmax (1 unit - increase, HR = 1.146, p = 0.008), SUVavg (1 unit - increase, HR = 1.469, p = 0.032) and treatment modality (non-surgical therapy vs. surgery, HR = 4.467, p = 0.002) were significant predictors for overall survival. On multivariate analyses, SUVmax (HR = 1.274, p = 0.015), treatment modality (HR = 3.353, p = 0.019) and necrosis (HR = 5.985, p = 0.006) were identified as significant independent prognostic factors associated with decreased overall survival. Conclusions: The SUVmax of the primary tumor is a significant independent metabolic prognostic factor for overall survival in patients with STS. Volume-based PET parameters may not add prognostic information outside of the SUVmax.
KW - Metabolic tumor volume
KW - PET/CT
KW - Prognosis
KW - Soft tissue sarcoma
KW - Standardized uptake value
UR - https://www.scopus.com/pages/publications/84898853775
U2 - 10.1007/s00256-014-1832-7
DO - 10.1007/s00256-014-1832-7
M3 - Article
C2 - 24531303
AN - SCOPUS:84898853775
SN - 0364-2348
VL - 43
SP - 641
EP - 648
JO - Skeletal Radiology
JF - Skeletal Radiology
IS - 5
ER -
